Immunexpress Closes $6M Financing Round led by Debiopharm

Immunexpress Group (Immunexpress) and Debiopharm Diagnostics SA (Debiopharm), have announced the securing of six million U.S. dollars from a financing round, led by Debiopharm.

The funding will be used to advance development of the Immunexpress SeptiCyte® technology and bring one of the company’s late-stage sepsis diagnostic products through to market.

Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Debiopharm Diagnostics SA is part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on investment in cutting edge diagnostic companies.

“The early detection of sepsis is critical. This revolutionary technology will utilize the early immune response to sepsis and potentially lead to a more targeted treatment approach for each patient, which may provide better outcomes for the patients who present with this life-threatening condition,” said Thierry Mauvernay, Delegate of the Board of Debiopharm Group.

Mauvernay continued, “Debiopharm and Immunexpress have been collaborating since June 2012 on the development of one of the Immunexpress investigational products for triaging patients in Emergency Rooms. We are impressed by their work and are confident that the future of sepsis management lies in the use of their innovative diagnostic technology.”

“This is an important milestone for Immunexpress and, ultimately, for the health care community worldwide which is in need of new, improved methods to more quickly and accurately identify and diagnose patients suspected of sepsis,” said Dr Roslyn Brandon, President and Chief Executive Officer, Immunexpress.

Dr Brandon continued, “Support and funding from Debiopharm will provide us with the resources necessary to advance and commercialize our proprietary SeptiCyte® technology for critical care patients.”